Literature DB >> 26706603

The clinical profile of tuberous sclerosis complex (TSC) in the United Kingdom: A retrospective cohort study in the Clinical Practice Research Datalink (CPRD).

Christopher Kingswood1, Patrick Bolton2, Pamela Crawford3, Christopher Harland4, Simon R Johnson5, Julian R Sampson6, Charles Shepherd7, Jayne Spink8, Dirk Demuth9, Lara Lucchese9, Paola Nasuti9, Elizabeth Gray10, Alun Pinnegar10, Matthew Magestro11.   

Abstract

BACKGROUND: Tuberous Sclerosis Complex (TSC) is a multi-system genetic disorder characterised by the development of benign growths and diverse clinical manifestations, varying in severity, age at onset and with high clinical burden. AIMS: This longitudinal study aims to describe the broad spectrum of clinical manifestation profiles in a large, representative cohort of TSC patients in the UK in order to better understand disease complexity.
METHODS: TSC patients in the Clinical Practice Research Datalink (CPRD) and linked Hospital Episodes Statistics (CPRD-HES) were retrospectively identified between 1987 and 2013. Available history was extracted for each patient and clinical diagnosis, procedure and medication records reviewed. A random selection of patients from the CPRD-HES was used as a Comparator cohort.
RESULTS: Three hundred and thirty-four TSC patients with a mean (SD) age of 30.3 (18.6) years were identified (53% female). TSC was diagnosed at mean age 3.2 (4.2) years. Epilepsy and psychiatric manifestations were reported frequently in paediatric (77% and 55%, respectively) and adult patients (66% and 68%, respectively). The prevalence of manifestations in the TSC cohort was markedly higher versus the Comparator cohort. The majority of paediatric (46%) and adult TSC patients (62%) developed clinical manifestations affecting at least three organ systems and forty-nine distinctive organ system manifestation profiles were identified.
CONCLUSIONS: TSC patients present with multiple and complex clinical manifestations and profiles that necessitate the co-ordinated action of a multidisciplinary team in order to improve the quality and efficiency of care.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Angiomyolipoma; Epilepsy; Prevalence manifestations; Retrospective database; Subependymal giant cell astrocytoma (SEGA); Tuberous sclerosis

Mesh:

Year:  2015        PMID: 26706603     DOI: 10.1016/j.ejpn.2015.11.011

Source DB:  PubMed          Journal:  Eur J Paediatr Neurol        ISSN: 1090-3798            Impact factor:   3.140


  24 in total

Review 1.  Tuberous sclerosis complex: new insights into clinical and therapeutic approach.

Authors:  Angela Volpi; Gabriele Sala; Elena Lesma; Francesca Labriola; Marco Righetti; Rosa Maria Alfano; Mario Cozzolino
Journal:  J Nephrol       Date:  2018-11-07       Impact factor: 3.902

Review 2.  Treatment of renal angiomyolipoma in tuberous sclerosis complex (TSC) patients.

Authors:  S Brakemeier; F Bachmann; K Budde
Journal:  Pediatr Nephrol       Date:  2016-09-01       Impact factor: 3.714

3.  [ESPED-Survey: TSC-disease in children and adolescents: preliminary results from a German epidemiological survey].

Authors:  Lilian Mann; Daniel Ebrahimi-Fakhari; Beate Heinrich; Marina Flotats-Bastardas; Ludwig Gortner; Alexander von Gontard; Justine Niemcyzk; Martin Poryo; Sascha Meyer
Journal:  Wien Med Wochenschr       Date:  2016-11-03

4.  Analysis of Clinical Features and Next-Generation Sequencing of 12 Tuberous Sclerosis Families in China.

Authors:  Xu Wang; Wenda Wang; Yang Zhao; Zhan Wang; Yushi Zhang
Journal:  Front Med (Lausanne)       Date:  2022-05-27

5.  Rhinencephalon changes in tuberous sclerosis complex.

Authors:  Renzo Manara; Davide Brotto; Samuela Bugin; Maria Federica Pelizza; Stefano Sartori; Margherita Nosadini; Sara Azzolini; Giorgio Iaconetta; Cecilia Parazzini; Alessandra Murgia; Angela Peron; Paola Canevini; Francesca Labriola; Aglaia Vignoli; Irene Toldo
Journal:  Neuroradiology       Date:  2018-06-17       Impact factor: 2.804

6.  Rapamycin and dexamethasone during pregnancy prevent tuberous sclerosis complex-associated cystic kidney disease.

Authors:  Morris Nechama; Yaniv Makayes; Elad Resnick; Karen Meir; Oded Volovelsky
Journal:  JCI Insight       Date:  2020-07-09

7.  Presentation and Diagnosis of Tuberous Sclerosis Complex in Infants.

Authors:  Peter E Davis; Rajna Filip-Dhima; Georgios Sideridis; Jurriaan M Peters; Kit Sing Au; Hope Northrup; E Martina Bebin; Joyce Y Wu; Darcy Krueger; Mustafa Sahin
Journal:  Pediatrics       Date:  2017-11-03       Impact factor: 7.124

8.  Everolimus for treatment of tuberous sclerosis complex-associated neuropsychiatric disorders.

Authors:  Darcy A Krueger; Anjali Sadhwani; Anna W Byars; Petrus J de Vries; David N Franz; Vicky H Whittemore; Rajna Filip-Dhima; Donna Murray; Kush Kapur; Mustafa Sahin
Journal:  Ann Clin Transl Neurol       Date:  2017-11-12       Impact factor: 4.511

9.  Renal neoplasms in tuberous sclerosis mice are neurocristopathies.

Authors:  Uchenna Unachukwu; Takayuki Shiomi; Monica Goldklang; Kiran Chada; Jeanine D'Armiento
Journal:  iScience       Date:  2021-06-04

10.  The effect of everolimus on renal angiomyolipoma in pediatric patients with tuberous sclerosis being treated for subependymal giant cell astrocytoma.

Authors:  John J Bissler; David N Franz; Michael D Frost; Elena Belousova; E Martina Bebin; Steven Sparagana; Noah Berkowitz; Antonia Ridolfi; J Christopher Kingswood
Journal:  Pediatr Nephrol       Date:  2017-10-09       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.